Skip to main content
. 2022 Jan 10;83(4):346–355. doi: 10.1016/j.humimm.2022.01.004

Fig. 5.

Fig. 5

Representation of a BsAb comprising Regdanvimab and BegelomabMAbs. In both the arms of mAbs, cyan color denotes the Crossover (CrossMAb) CH-CL changes, whereas cyan color represents the KIH modifications in the Fc region. All the amino acid residue modifications have shown in circle form. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)